病毒性結膜炎治療市場按藥物類別、病毒類型、通路和地區分類

病毒性結膜炎治療市場規模預計在 2025 年為 3.75 億美元，預計到 2032 年將達到 5.312 億美元，2025 年至 2032 年的複合年成長率為 5.1%。

病毒性結膜炎是由多種病毒引起的急性結膜感染疾病，包括腺病毒和單純皰疹病毒。病毒性結膜炎佔感染性結膜炎的大多數，佔病例的 75%。病毒性結膜炎的特徵包括眼紅、血管充血、眼分泌物、疼痛和畏光。由腺病毒組引起的病毒性結膜炎稱為流行性角結膜炎 (EKC)。這組腺病毒具有多種血清型，也可引起咽結膜熱和特異性濾泡性結膜炎。根據發表在《美國眼科學會：2018》上的一篇論文，腺病毒性結膜炎是成人族群中最常見的眼部感染疾病。腺病毒性結膜炎傳染性極強，因為引起感染的病毒可以在工作檯面和類似表面存活數週。

市場動態

開發人員正在進行臨床試驗，以開發更有效的腺病毒性結膜炎治療方法，這很可能在預測期內促進市場成長。例如，2017年，工業的子公司Shire Plc開始進行臨床試驗，以檢驗其候選藥物SHP640在治療成人和兒童腺病毒性結膜炎的安全性和有效性。

市場參與企業正專注於推出新產品，預計這些產品將鞏固其在全球市場的地位。例如，2018年，艾伯維公司（Abbvie Inc.）的子公司艾爾建公司（Allergan plc.）推出了一款新的非處方（OTC）人工淚液配方「Refresh Repair潤滑眼藥水」。此配方含有羧甲基纖維素鈉（CMC）、透明質酸（HA，非活性成分）和滲透保護劑，可保護眼睛免受結膜發炎症狀（例如乾眼症）的不利影響。

市場參與企業正積極與其他公司建立夥伴關係關係，加強分銷，從而擴大其全球影響力，預計這將推動病毒性結膜炎藥物市場的成長。例如，2018年，德國萌蒂製藥公司（Mundipharma Deutschland GmbH & Co.KG）與義大利製藥公司NTC建立商業合作夥伴關係，獲得在拉丁美洲授權和分銷一系列眼科藥物的獨家權利，從而擴大了其在拉丁美洲的眼科藥物組合。

研究的主要特點

• 本報告對全球病毒性結膜炎治療市場進行了詳細分析，並以 2024 年為基準年，對 2025 年至 2032 年期間的市場規模進行了預測。
• 它揭示了不同領域的潛在商機，並解釋了該市場的有吸引力的投資提案矩陣。
• 它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、區域前景以及主要企業採用的競爭策略的重要見解。
• 全球病毒性結膜炎治療市場的主要企業已根據公司概況、財務績效、產品系列、地理位置、分銷策略、關鍵發展和策略以及未來計劃等參數進行了分析。
• 本報告的見解將使負責人和企業經營團隊能夠就未來的產品發布、技術改進、市場擴張和行銷策略做出明智的決策。
• 全球病毒性結膜炎治療藥物市場報告涉及該行業的各個相關人員，例如投資者、供應商、製造商、經銷商、新進入者和金融分析師。
• 相關人員可以透過病毒性結膜炎藥物市場分析中使用的各種策略矩陣更輕鬆地做出決策。

目錄

第1章 研究目的與前提

• 研究目標
• 先決條件
• 簡稱

第2章 市場展望

• 報告描述
  • 市場定義和範圍
• 執行摘要

第3章市場動態、法規與趨勢分析

• 市場動態
  • 驅動程式
  • 限制因素
  • 市場機會
• 影響分析
• 最近的測試啟動
• 流行病學
• 合併、收購與合作
• 監管情景
• PEST分析

4. 2020 年至 2032 年全球病毒性結膜炎藥物市場（依藥物類別）

• 介紹
• 抗生素
• 人工淚液
• 鼻減充血劑
• 抗組織胺藥
• NSAIDs
• 抗病毒藥物
• 其他

5. 全球病毒性結膜炎藥物市場（依病毒類型分類），2020 年至 2032 年

• 介紹
• 腺病毒
• 腸病毒
• 其他（單純皰疹病毒（HSV）等）

6. 2020-2032 年全球病毒性結膜炎藥物市場（依通路）

• 介紹
• 醫院藥房
• 零售藥局
• 網路藥局

7. 2020 年至 2032 年全球病毒性結膜炎藥物市場（按地區）

• 介紹
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 英國
  • 德國
  • 義大利
  • 法國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 東南亞國協
  • 澳洲
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲
• 中東
  • 海灣合作理事會國家
  • 以色列
  • 其他中東地區
• 非洲
  • 北非
  • 中部非洲
  • 南非

第8章 競爭態勢

• 公司簡介
  • AbbVie Inc.
  • Takeda Pharmaceutical Company Limited
  • Bausch Health Companies Inc.
  • Panoptes Pharma Ges.mbH
  • NovaBay Pharmaceuticals, Inc.
  • Nicox, NanoViricides Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Johnson & Johnson
  • GlaxoSmithKline Plc.
  • Santen Pharmaceutical Co.Ltd.
  • Alcon
  • Okogen Inc.

第9章 章節

• 參考
• 調查方法

Viral Conjunctivitis Drugs Market is estimated to be valued at USD 375 Mn in 2025 and is expected to reach USD 531.2 Mn by 2032, growing at a compound annual growth rate (CAGR) of 5.1% from 2025 to 2032.

Viral conjunctivitis is an acute conjunctival infection that is caused due to various viruses such adenovirus, herpes simplex virus etc. Viral conjunctivitis is responsible for majority of infectious conjunctivitis accounting for up to 75% of cases. Characteristics of occular viral conjunctivitis include redness, blood vessel engorgement, ocular discharge, pain, photophobia etc. Viral conjunctivitis that is caused by a group of adenoviruses is called Epidemic Keratoconjunctivitis (EKC). This family of adenoviruses contains different serotypes that can cause pharyngoconjunctival fever and nonspecific follicular conjunctivitis as well. According to the article published in the American Academy of Ophthalmology: 2018, adenoviral conjunctivitis is the most common type of eye infection in adult population. The adenoviral conjunctivitis is highly contagious as the virus causing the infection can survive on a countertop or a similar surface for several weeks.

Market Dynamics

Market players are conducting clinical trials for developing more efficient treatments for adenoviral conjunctivitis, which could contribute to the growth of the market over the forecast period. For instance, in 2017, Shire Plc, subsidiary of Takeda Pharmaceutical Company, initiated clinical trials for testing the safety and efficacy of its drug candidate SHP640 for the treatment of adults and children suffering from adenoviral conjunctivitis.

Market players are focusing on the launch of new products, which is expected to strengthen their position in the global market. For instance, in 2018, Allergan plc., a subsidiary of Abbvie Inc., launched a new over-the-counter (OTC) artificial tear formulation, REFRESH REPAIR Lubricant Eye Drops. It is formulated with carboxymethylcellulose (CMC), hyaluronic acid (HA, an inactive ingredient), and osmoprotectants that protects the eyes from the harmful effects of conjunctivitis symptoms like dry eyes.

Market players are involved in expanding their global presence by entering into partnerships with other companies in order to enhance distribution, this is expected to drive the growth of the viral conjunctivitis drugs market. For instance, in 2018, Mundipharma Deutschland GmbH & Co. KG, a pharmaceutical company, expanded its ophthalmology portfolio in Latin America by entering into a commercial partnership with NTC - an Italian pharmaceutical company, for obtaining exclusive rights to license and distribute a range of ophthalmic medicines across the Latin America region.

Key features of the study

• This report provides an in-depth analysis of global viral conjunctivitis drugs market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players.
• It profiles leading players in the global viral conjunctivitis drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
• Key companies covered as a part of this study include AbbVie Inc., Takeda Pharmaceutical Company Limited, Bausch Health Companies Inc., Panoptes Pharma Ges.m.b.H, NovaBay Pharmaceuticals, Inc., Nicox, NanoViricides Inc., Novartis International AG, Pfizer Inc., Johnson & Johnson, GlaxoSmithKline Plc., and Okogen Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics.
• The global viral conjunctivitis drugs market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision making through various strategy matrices used in analyzing the viral conjunctivitis drugs market.

Market Segmentation

• Global Viral Conjunctivitis Drugs Market, By Drug Class
  • Artificial tears
  • Decongestants
  • Anti-histamines
  • NSAIDS
  • Anti-Viral drugs
  • Steroids
  • Antibiotics
• Global Viral Conjunctivitis Drugs Market, By Virus Type
  • Adenovirus
  • Enterovirus
  • Others
• Global Viral Conjunctivitis Drugs Market, By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Viral Conjunctivitis Drugs Market, By Region
  • North America
  • By Drug Class
  • Artificial tears
  • Decongestants
  • Anti-histamines
  • NSAIDS
  • Anti-Viral drugs
  • Steroids
  • Antibiotics
  • By Virus Type
  • Adenovirus
  • Enterovirus
  • Others
  • By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country
  • U.S.
  • Canada
  • Latin America
  • By Drug Class
  • Artificial tears
  • Decongestants
  • Anti-histamines
  • NSAIDS
  • Anti-Viral drugs
  • Steroids
  • Antibiotics
  • By Virus Type
  • Adenovirus
  • Enterovirus
  • Others
  • By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • By Drug Class
  • Artificial tears
  • Decongestants
  • Anti-histamines
  • NSAIDS
  • Anti-Viral drugs
  • Steroids
  • Antibiotics
  • By Virus Type
  • Adenovirus
  • Enterovirus
  • Others
  • By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country
  • U.K.
  • Germany
  • Italy
  • Spain
  • France
  • Russia
  • Rest of Europe
  • Asia Pacific
  • By Drug Class
  • Artificial tears
  • Decongestants
  • Anti-histamines
  • NSAIDS
  • Anti-Viral drugs
  • Steroids
  • Antibiotics
  • By Virus Type
  • Adenovirus
  • Enterovirus
  • Others
  • By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Middle East
  • By Drug Class
  • Artificial tears
  • Decongestants
  • Anti-histamines
  • NSAIDS
  • Anti-Viral drugs
  • Steroids
  • Antibiotics
  • By Virus Type
  • Adenovirus
  • Enterovirus
  • Others
  • By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • By Drug Class
  • Artificial tears
  • Decongestants
  • Anti-histamines
  • NSAIDS
  • Anti-Viral drugs
  • Steroids
  • Antibiotics
  • By Virus Type
  • Adenovirus
  • Enterovirus
  • Others
  • By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country/Region
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
  • AbbVie Inc.
  • Takeda Pharmaceutical Company Limited
  • Bausch Health Companies Inc.
  • Panoptes Pharma Ges.m.b.H
  • NovaBay Pharmaceuticals, Inc.
  • Nicox
  • NanoViricides Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Johnson & Johnson
  • GlaxoSmithKline Plc.
  • Okogen Inc.

Table of Contents

1. Research Objective and Assumption

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Drug Class
  • Market Snippet, By Virus Type
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Recent Test Launches
• Epidemiology
• Merger, Acquisition, and Collaborations
• Regulatory Scenario
• Key Developments
• PEST Analysis

4. Global Viral Conjunctivitis Drugs Market, By Drug Class, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021-2032
  • Segment Trends
• Antibiotics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Segment Trends
• Artificial tears
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Segment Trends
• Decongestants
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Segment Trends
• Anti-histamines
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Segment Trends
• NSAIDS
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Segment Trends
• Anti-Viral drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Segment Trends
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 -2032, (USD Mn)
  • Segment Trends

5. Global Viral Conjunctivitis Drugs Market, By Virus Type, 2020 - 2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021-2032
  • Segment Trends
• Adenovirus
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Mn)
  • Segment Trends
• Enterovirus
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Mn)
  • Segment Trends
• Others (Herpes Simplex Virus (HSV), etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Mn)
  • Segment Trends

6. Global Viral Conjunctivitis Drugs Market, By Distribution Channel, 2020 - 2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021-2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

7. Global Viral Conjunctivitis Drugs Market, By Region, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021-2032
  • Segment Trends
• North America
  • Introduction
  • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2020-2032, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2020-2032, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2020-2032, (USD Mn)
  • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020-2032, (USD Mn)
    • U.S.
    • Canada
• Europe
  • Introduction
  • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2020-2032, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2020-2032, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2020-2032, (USD Mn)
  • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020-2032, (USD Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2020-2032, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2020-2032, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2020-2032, (USD Mn)
  • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020-2032, (USD Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2020-2032, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2020-2032, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2020-2032, (USD Mn)
  • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020-2032, (USD Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2020 -2032, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2020-2032, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2020-2032, (USD Mn)
  • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020-2032, (USD Mn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2020-2032, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2020-2032, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2020-2032, (USD Mn)
  • Market Size and Forecast, By Country, Y-o-Y Growth and By Country/ Region, 2020-2032, (USD Mn)
    • North Africa
    • Central Africa
    • South Africa

8. Competitive Landscape

• Company Profiles
  • AbbVie Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Takeda Pharmaceutical Company Limited
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Bausch Health Companies Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Panoptes Pharma Ges.m.b.H
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • NovaBay Pharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Nicox, NanoViricides Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Novartis International AG
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Pfizer Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Johnson & Johnson
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • GlaxoSmithKline Plc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Santen Pharmaceutical Co.Ltd.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Alcon
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Okogen Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies

9. Section

• References
• Research Methodology
• About us and Sales Contact